A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD) patients
Phase 1
Recruiting
- Conditions
- Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease (HD), Multiple Sclerosis (MS)MedDRA version: 20.0Level: PTClassification code: 10070668Term: Huntington's disease Class: 100000004850MedDRA version: 20.0Level: LLTClassification code: 10001896Term: Alzheimer's disease Class: 10029205MedDRA version: 21.1Level: PTClassification code: 10002026Term: Amyotrophic lateral sclerosis Class: 100000004852MedDRA version: 20.1Level: PTClassification code: 10028245Term: Multiple sclerosis Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2023-507195-43-00
- Lead Sponsor
- Mitochon Pharmaceuticals Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does MP-101 target in neurodegenerative diseases like HD, ALS, MS, and AD?
How does MP-101 compare to standard-of-care treatments in Huntington’s Disease and Alzheimer’s Disease?
Which biomarkers are used for patient selection in Mitochon Pharmaceuticals' MP-101 phase I trial for neurodegenerative diseases?
What are the potential adverse events associated with MP-101 in early-phase trials for amyotrophic lateral sclerosis and multiple sclerosis?
Are there any combination therapies or competitor drugs targeting mitochondrial function in Huntington’s Disease and Alzheimer’s Disease similar to MP-101?